Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines

Eli Lilly and peers such as Novartis are fueling a 2026 pharma M&A surge with multiple billion-dollar ($1B+) deals to expand pipelines, acquire AI capabilities, and counter patent-expiration pressures. The wave accelerates sector consolidation, strengthens near-term R&D pipelines and tech-enabled drug discovery, and could re-rate individual biotech and large-cap pharma equities as strategic assets and pipelines are reshaped.

Analysis

Eli Lilly and peers such as Novartis are fueling a 2026 pharma M&A surge with multiple billion-dollar ($1B+) deals to expand pipelines, acquire AI capabilities, and counter patent-expiration pressures. The wave accelerates sector consolidation, strengthens near-term R&D pipelines and tech-enabled drug discovery, and could re-rate individual biotech and large-cap pharma equities as strategic assets and pipelines are reshaped.